![]() |
市場調查報告書
商品編碼
1820145
甲狀腺功能測試市場報告,按測試類型(TSH 測試、T3 測試、T4 測試等)、適應症(甲狀腺功能減退症、甲狀腺功能亢進症、甲狀腺癌等)、最終用戶(醫院、診斷實驗室等)和地區分類,2025 年至 2033 年Thyroid Function Test Market Report by Test Type (TSH Tests, T3 Tests, T4 Tests, and Others), Indication (Hypothyroidism, Hyperthyroidism, Thyroid Cancer, and Others), End User (Hospitals, Diagnostic Laboratories, and Others), and Region 2025-2033 |
2024年,全球甲狀腺功能檢測市場規模達17億美元。展望未來, IMARC Group預計到2033年,該市場規模將達到26.3億美元,2025-2033年期間的複合年成長率(CAGR)為4.9%。檢測設備在精度、速度和可靠性方面的不斷進步,個人對家用檢測試劑盒的需求不斷成長,以及對甲狀腺疾病早期發現和治療的日益重視,都是推動市場成長的一些因素。
診斷技術的進步
自動化檢測系統、高通量分析儀和即時檢測 (POC) 等創新技術正在提升甲狀腺檢測的精確度、速度和便利性。這些技術使醫療保健提供者能夠更快地提供結果,從而更輕鬆地診斷和治療甲狀腺疾病。此外,人工智慧 (AI) 和機器學習 (ML) 在診斷工具中的整合也提高了甲狀腺檢測的預測精準度,從而為患者提供更高水準的個人化治療。此外,家用檢測試劑盒的出現簡化了患者(尤其是偏遠地區或行動不便的患者)監測甲狀腺健康狀況的過程。檢測技術的不斷發展推動了醫療保健機構對甲狀腺功能檢測的需求。 2023 年,西普拉 (Cipla) 推出了 Cippoint,這是一款即時檢測設備,可快速檢測各種健康問題,例如心臟標記、糖尿病和甲狀腺功能。該設備已獲得 CE IVD 認證,可在 3 至 15 分鐘內得出結果,有助於加快臨床決策。 Cippoint 秉持著簡化設計的理念,致力於提升城鄉醫療環境中的診斷能力。
提高家庭檢測試劑盒的可及性
人們正在尋求便利的醫療保健選擇,這推動了家用檢測試劑盒的需求,因為它們能夠追蹤甲狀腺指標,無需頻繁前往實驗室。持續的技術進步使家用檢測選項更加可靠和精確,使人們能夠主動管理自身健康。這一趨勢對於那些因地域或時間限制而難以獲得傳統醫療服務的人尤其具有吸引力。此外,在家中舒適地進行檢測的能力正在鼓勵更多人接受甲狀腺篩檢,這為甲狀腺功能檢測市場帶來了良好的前景。 2023年,Healthyr與沃爾瑪合作推出了六款家用乾血斑檢測試劑盒,標誌著它們首次登陸實體店。這些檢測涵蓋了各種健康指標,例如一般健康、膽固醇、糖化血紅蛋白+血糖、甲狀腺功能和性傳染感染 (STI),可在線上或在超過1200家沃爾瑪門市購買。該計畫旨在透過提供便捷易得的檢測選項,幫助人們管理自身健康。
意識增強和預防保健
隨著醫療保健系統轉向積極主動的策略,甲狀腺疾病和其他慢性疾病的早期發現和治療日益受到重視。關於甲狀腺健康重要性的公眾意識宣傳活動和教育計劃正在鼓勵人們定期進行篩檢,尤其是女性和老年人等高風險族群。透過在藥局等日常場所推廣自我檢測,這些措施促進了人們自主掌控自身健康的日益成長的趨勢。這種積極主動的方法正在支持甲狀腺功能檢測市場的成長,因為越來越多的人認知到常規甲狀腺篩檢對整體健康管理的價值。 2023年,2San和Phoenix Healthcare在藥局推出了包括甲狀腺檢測在內的各種自我診斷檢測,以改善個人醫療保健。這些檢測在380家Rowlands藥局分店和5200家Numark獨立藥局提供。目標是使自我檢測更加普及,使人們能夠及早發現健康問題並在需要時尋求幫助。
TSH 測試佔據大部分市場佔有率
TSH 檢測因其在甲狀腺疾病診斷和監測中的廣泛應用而佔據市場主導地位。促甲狀腺激素 (TSH) 檢測是檢測甲狀腺功能減退症和甲狀腺功能亢進症的主要診斷工具,因為它可以測量調節甲狀腺功能的荷爾蒙。由於 TSH 檢測的準確性、可靠性和成本效益,臨床醫生更傾向於將其用於甲狀腺的初步篩檢和常規監測。 TSH 檢測的廣泛應用和可靠性顯著擴大了甲狀腺功能檢測的整體市場規模,使其成為行業中的主導細分市場。
甲狀腺功能減退症佔業界最大佔有率
甲狀腺功能減退症是最大的細分市場,這歸因於其在世界範圍內的高發病率和頻繁監測的需求。甲狀腺功能減退症是由於甲狀腺激素分泌不足引起的,會導致疲勞、體重增加和悲傷等症狀。這種疾病在老年人和女性中尤其常見,隨著醫療保健意識的提高和常規篩檢的普及,確診病例的數量也不斷增加。甲狀腺功能減退症需要透過定期甲狀腺功能檢測持續監測荷爾蒙水平,這推動了此類檢測的需求。 2024年,海得拉巴的Niloufer醫院啟動了一項新生兒篩檢項目,旨在識別先天性甲狀腺功能減退症和G6PD缺乏症等嚴重的遺傳性疾病。篩檢包括在出生後24至48小時內進行的足跟採血檢查,通常在5至7天內即可獲得結果。該計畫是印度一項旨在加強罕見疾病早期診斷和管理的大型活動的組成部分。
醫院是主要的細分市場
醫院因其龐大的患者數量和先進的診斷設施而佔據最大的市場佔有率。醫院通常是甲狀腺疾病患者的主要治療機構,提供一系列服務,例如專業的內分泌科和先進的檢測工具。此外,醫院通常處理更複雜的情況,例如甲狀腺手術和癌症治療,這些情況需要持續監測甲狀腺功能。因此,隨著醫院內患者對全面診斷和監測解決方案的需求不斷成長,甲狀腺功能檢測市場的價值正在上升。
北美領先市場,佔據甲狀腺功能檢測最大市場佔有率
該報告還對所有主要區域市場進行了全面分析,包括北美(美國和加拿大);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。報告指出,北美是甲狀腺功能檢測最大的區域市場。
北美佔據市場主導地位,因為其擁有先進的醫療設施、高昂的醫療支出以及大量甲狀腺問題患者。對預防性醫療保健和定期篩檢的高度重視推動了對甲狀腺功能測試的需求。此外,橋本甲狀腺炎和格雷夫茲病等自體免疫疾病在北美的盛行率相對較高,進一步推動了對持續甲狀腺監測的需求。主要市場參與者的存在以及診斷技術的持續研究和創新正在促進市場成長。美國癌症協會預測,2024 年美國將新增約 44,020 例甲狀腺癌病例,其中男性 12,500 例,女性 31,520 例。此外,估計約有 2,170 人死於甲狀腺癌,其中男性 990 例,女性 1,180 例。
(請注意,這只是關鍵參與者的部分名單,完整名單在報告中提供。)
The global thyroid function test market size reached USD 1.70 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.63 Billion by 2033, exhibiting a growth rate (CAGR) of 4.9% during 2025-2033. The growing advancements in testing devices for enhancing precision, speed, and reliability, rising demand for at-home testing kits among individuals, and increasing emphasis on early detection and treatment of thyroid disorders are some of the factors impelling the market growth.
Advances in Diagnostic Technologies
Innovations, like automated testing systems, high-throughput analyzers, and POC testing devices, are enhancing the precision, speed, and ease of thyroid testing. These technologies allow healthcare providers to provide faster outcomes, making it easier to diagnose and treat thyroid disorders. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) in diagnostic tools is improving the predictive precision of thyroid tests, leading to a higher level of tailored patient treatment. Furthermore, the creation of testing kits for use at home are simplifying the process of monitoring thyroid health for patients, particularly those in remote locations or individuals experiencing mobility challenges. The growing advancements in testing technology are driving the thyroid function test demand in healthcare settings. In 2023, Cipla revealed Cippoint, a device for POC testing that offered rapid testing for various health issues, such as cardiac markers, diabetes, and thyroid function. CE IVD approved, the device produced outcomes within a 3 to 15 minutes timeframe, aiding in faster clinical decision-making. Created for simplicity, Cippoint strived to improve diagnostic abilities in urban and rural healthcare environments.
Increasing Accessibility of At-Home Testing Kits
Individuals are looking for convenient healthcare options, which is driving the demand for at-home testing kits because of their ability to track thyroid without the need for frequent laboratory visits. The continuous technological progress is making home testing options more dependable and precise, empowering individuals to manage their health actively. This trend is particularly appealing to those who may have difficulty accessing traditional healthcare services because of geographical or time constraints. Furthermore, the ability to perform tests comfortably at home is encouraging more people to undergo thyroid screening, offering a favorable thyroid function test market outlook. In 2023, Healthyr introduced six dried blood spot test kits for home use in partnership with Walmart, marking their debut in brick-and-mortar stores. The available tests cover various health aspects like general health, cholesterol, HbA1c + glucose, thyroid function, and sexually transmitted infections (STIs), and can be purchased online or at over 1,200 Walmart stores. This project seeks to enable people to manage their health by offering convenient and easily accessible testing options.
Growing Awareness and Preventive Healthcare
With healthcare systems moving towards proactive strategies, there is an emphasis on early detection and treatment of thyroid disorders and other chronic conditions. Public awareness campaigns and educational initiatives about the significance of thyroid health are encouraging individuals to seek regular screenings, particularly those at higher risk, such as women and older adults. By promoting self-testing in everyday settings like pharmacies, these efforts contribute to the growing trend of empowering people to take control of their health. This proactive approach is supporting the thyroid function test market growth, as more individuals recognize the value of routine thyroid screening for overall health management. In 2023, 2San and Phoenix Healthcare introduced a variety of self-diagnostic tests in pharmacies, including a thyroid test, to improve individual health care. These tests were made available at 380 Rowlands Pharmacy branches and 5,200 Numark independent pharmacies. The goal was to make self-testing more common, enabling people to detect health problems early and seek help as needed.
TSH tests account for the majority of the market share
TSH tests dominate the market because of their widespread use in diagnosing and monitoring thyroid disorders. Thyroid stimulating hormone (TSH) tests are the primary diagnostic tool for detecting both hypothyroidism and hyperthyroidism, as they measure the hormone that regulates the thyroid gland's function. Clinicians prefer using TSH tests for initial thyroid screenings and routine monitoring due to their accuracy, reliability, and cost-effectiveness. The extensive usage and reliability of TSH tests notably contribute to the overall thyroid function test market size, making it a dominant segment in the industry.
Hypothyroidism holds the largest share of the industry
Hypothyroidism represents the largest segment attributed to its high prevalence worldwide and the requirement for frequent monitoring. Hypothyroidism is the result of inadequate hormone production by the thyroid gland, causing symptoms like tiredness, increased weight, and feelings of sadness. The condition is particularly common in older adults and women, with a growing number of cases being diagnosed due to increased healthcare awareness and routine screenings. Hypothyroidism requires continuous monitoring of hormone levels through regular thyroid function testing, which is driving the demand for these tests. In 2024, Niloufer Hospital in Hyderabad initiated a newborn screening program to identify serious genetic disorders like congenital hypothyroidism and G6PD deficiency. The screening includes a heel prick test done between 24 and 48 hours after birth, with results typically ready in five to seven days. This project is a component of a larger campaign to enhance the early diagnosis and management of rare diseases in India.
Hospitals represent the leading market segment
Hospitals hold the biggest market share because of the large patient volume and the presence of advanced diagnostic facilities. Hospitals are commonly the main source of treatment for individuals with thyroid issues, providing a range of services such as specialized endocrinology units and advanced testing tools. Furthermore, hospitals often deal with more intricate situations like thyroid surgeries and cancer treatments that necessitate continuous monitoring of thyroid function. As a result, the thyroid function test market value is rising, driven by the growing demand for comprehensive diagnostic and monitoring solutions among patients within hospital settings.
North America leads the market, accounting for the largest thyroid function test market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for thyroid function test.
North America dominates the market because of advanced healthcare facilities, high healthcare expenditure, and a large population with thyroid issues. The strong focus on preventive healthcare and regular screenings is driving the demand for thyroid function tests. Additionally, the prevalence of autoimmune diseases, such as Hashimoto's thyroiditis and Graves' disease, is relatively high in North America, further driving the need for consistent thyroid monitoring. The presence of key market players and continuous research and innovation in diagnostic technologies is bolstering the market growth. The American Cancer Society predicts around 44,020 new thyroid cancer cases in the United States in 2024, including 12,500 in men and 31,520 in women. Moreover, the estimates suggest about 2,170 fatalities due to thyroid cancer, with 990 in males and 1,180 in females.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)